rates

ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cyclesESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles

ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles

A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology…

3 weeks ago
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused…

1 month ago
CoinDesk Overnight Rates (CDOR) to Support Stablecoin Money Markets based on AaveCoinDesk Overnight Rates (CDOR) to Support Stablecoin Money Markets based on Aave

CoinDesk Overnight Rates (CDOR) to Support Stablecoin Money Markets based on Aave

These first-of-kind money market rates transform Aave pool activity into conventional overnight rates to support interest rate derivatives and floating…

1 month ago
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

1 month ago
Manufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading PerformanceManufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading Performance

Manufacturers and Logistics Providers Embrace AI for Enhanced Barcode Reading Performance

Survey reveals 90% of users anticipate AI will improve accuracy, ease of use, decode rates, and more NATICK, Mass., June…

2 months ago